Curis Inc (NASDAQ: CRIS) is a clinical-stage oncology biotechnology company focused on developing small molecule cancer therapies. Revenue is generated primarily through royalties, which totaled $9.4 million in FY2025, down 13% from $10.9 million in FY2024. The company's sole active program is emavusertib, a dual inhibitor of IRAK4 and FLT3 kinases being evaluated in hematologic malignancies including AML, CLL, and PCNSL. Curis reported a net loss of $7.6 million in FY2025, against research and development expenses of $28.3 million and general and administrative expenses of $14.0 million. The company completed a PIPE financing in January 2026 for net proceeds of approximately $18.6 million, but disclosed in its 10-K filed March 24, 2026 that current cash is not expected to fund operations beyond 12 months from that filing date, raising substantial going-concern doubt. Competitors include large pharmaceutical and biopharmaceutical companies with substantially greater financial and operational resources.

Revenue model

Royalty income is the primary revenue source, generating $9.4 million in FY2025 (vs. $10.9 million in FY2024). The company has no approved products of its own and has not yet generated product revenue from emavusertib.

Products and services

Emavusertib: a small molecule dual inhibitor of IRAK4 and FLT3, in clinical development for AML (including FLT3-mutated and frontline combinations with azacitidine and venetoclax), CLL, and PCNSL (per 10-K filed 2026-03-24).

Customers and end markets

End markets are hematologic oncology, specifically acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and primary central nervous system lymphoma (PCNSL). No product revenue customers are disclosed; royalty counterparty not identified in the provided excerpts.

Value-chain role

Clinical-stage drug developer. Curis conducts its own research and clinical trials for emavusertib and collects royalties on a separate commercialized asset. It does not manufacture or commercialize its own approved products as of the filing date.

Geographic exposure

Headquartered in the United States. Subject to U.S. federal and state privacy and regulatory frameworks. No international revenue breakdown disclosed in the provided excerpts.

Competitors

Faron Pharmaceuticals Oy (bexmarilimab), Novartis AG (sabatolimab), OncoVerity Inc. (cusatuzumab), Glycomimetics Inc. (uproleselan), Shattuck Labs Inc. (SL-17254), Bio-Path Holdings Inc. (prexigebersen), Astellas Pharma Inc. (gilteritinib), AbbVie Inc. (pivekimab sunirine), Kurome Therapeutics (IRAK4 inhibitor, preclinical)

Source: SEC 10-K, filed 2026-03-24

Industry: Biological Products, (No Diagnostic Substances) Peers: X4 Pharmaceuticals Inc ZEO ScientifiX Inc Bolt Biotherapeutics Inc Senti Biosciences Inc Equillium Inc Korro Bio Inc Synlogic Inc Pyxis Oncology Inc SQZ Biotechnologies Co